Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study

Launched by BEIJING TIANTAN HOSPITAL · Nov 8, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study, is looking at how long patients need to take certain medications after receiving a special stent (a small tube that helps keep arteries open) for a condition called vertebral artery stenosis, which is a narrowing of the arteries in the neck. The goal is to determine if patients can safely take these medications for a shorter time, which could lower their risk of bleeding and make treatment easier, without causing more strokes or other serious problems.

To participate in the study, you need to be at least 18 years old and have symptoms related to the narrowing of your vertebral arteries. The researchers will be looking for patients who meet specific health criteria, so not everyone will qualify. If you do participate, you can expect to receive the stent and follow-up care, and the study will help improve future treatment options for others in similar situations. This trial is still in the planning stages and has not yet started recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years old, gender unlimited;
• • 2. Based on clinical and imaging evidence, the investigators identified patients with symptomatic vertebral atherosclerotic stenosis who met the indications for the placement of drug-eluting vertebral artery stents;
• • 3. Patients or their guardians sign informed consent.
• Exclusion Criteria:
• • 1. Severe coagulation dysfunction, serious uncontrolled infection, serious systemic disease, uncontrolled hypertension, etc., are not suitable for surgery;
• • 2. Patients with aneurysms that cannot be treated in advance or at the same time or are not suitable for surgery;
• • 3. Myocardial infarction or large-scale cerebral infarction occurred within 2 weeks;
• • 4. Combined with atrial fibrillation, or accompanied by serious heart, liver, kidney and lung diseases;
• • 5. Interventional or surgical procedures are planned within 90 days;
• • 6. Known contraindications to heparin, rapamycin, anesthesia and contrast agents;
• • 7. Life expectancy is less than 12 months;
• • 8. The researcher considers it inappropriate to participate in this study.